Short Build in Biotech
Biopharmaceutical firm Liquidia (LQDA) has experienced a significant increase in bearish sentiment. In the five days leading to October 28, short interest in the $4.1 billion market-cap company jumped by 7.8 percentage points, reaching 26.8% of free float.
Actionable Insight
The fresh short build suggests that professional traders are positioning for downside pressure ahead of potential news regarding the company's pipeline. As a contested name in the pulmonary hypertension space, LQDA is seeing heightened volatility as shorts look to capitalize on the recent buildup in bearish exposure.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.